Form 4: Kiniksa Pharmaceuticals International, plc: Chief Medical Officer Reports Stock Transactions

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares on May 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 7, 2025, John F. Paolini, the Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving the company's Class A Ordinary Shares.
• Paolini acquired 200 shares at a price of $3.8 per share and disposed of 200 shares at a price of $27 per share.
• These transactions were executed under a Rule 10b5-1 trading plan established on May 16, 2024.
• Following these transactions, Paolini directly owns 57,403 Class A Ordinary Shares.
• Paolini also holds options for 65,867 Class A Ordinary Shares, which are fully vested and exercisable as of June 28, 2027.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It is common for executives to use Rule 10b5-1 plans to schedule stock transactions in advance to avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they provide insight into the actions of a key executive.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, Form 4, Beneficial Ownership, John F. Paolini, Chief Medical Officer, Class A Ordinary Shares, Rule 10b5-1 plan, Stock Transactions, Insider Trading